Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a notable decline in its stock price during the last trading session, closing down 3.18%.
Investors in Cardiol Therapeutics Inc Class A are facing a challenging day as the stock slid by 3.18%, closing at CA$1.52. This drop comes amid no significant news to explain the downturn, leaving many to speculate on the underlying factors affecting market sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$165.99M
52W high
$2.33
52W low
$1.23
1W change
-1.96%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+300.0% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.1%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.25 โ C$1.60 |
| 60 trading days | C$1.33 | C$1.12 โ C$1.58 |
| 90 trading days | C$1.25 | C$1.02 โ C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Cardiol Therapeutics has been making strides in its clinical trials, today's performance may raise concerns about investor confidence and market dynamics.
Cardiol Therapeutics Market Cap at CA$180.98 Million
Despite a market cap of CA$180.98 million, the stock's recent performance suggests that investor sentiment may be wavering.
Bull case
The company's ongoing clinical trials, especially the Phase III MAVERIC trial, show promise for future growth. If the results continue to be positive, it could lead to significant advancements for the company.
Bear case
The lack of recent positive news or developments has led to a decline in the stock, reflecting investor uncertainty. This situation might indicate a lack of confidence in the company's near-term prospects.
Market Reaction to Cardiol's Recent Developments
Despite recent advancements, including the acceptance of Phase II MAVERIC results for publication, the stock's decline suggests that investors are looking for more immediate positive catalysts. The absence of recent news could be contributing to the downward pressure.
Understanding Investor Sentiment
Investor sentiment plays a crucial role in stock performance. The decline in Cardiol Therapeutics' stock may reflect broader market concerns or specific anxieties about the company's future, particularly in light of its current market cap and lack of dividends.
Looking Ahead: Whatโs Next for CRDL.TO?
As Cardiol Therapeutics continues to engage in pivotal trials, investors will be closely monitoring upcoming announcements and results. The trajectory of the stock will largely depend on how these developments are perceived in the market.
Advertisement
